Market Place
Sourcing Support
Hart-Scott-Rodino waiting period expires for Sanofi acqu. of Provention Bio
26 Apr 2023 //
GLOBENEWSWIRE
Sanofi`s Provention buy hit with FTC delay
11 Apr 2023 //
FIERCE PHARMA
Sanofi to acquire Provention Bio for $2.9 billion
14 Mar 2023 //
PRESS RELEASE
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release
13 Mar 2023 //
PR NEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
03 Mar 2023 //
PR NEWSWIRE
Provention to Report Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
PR NEWSWIRE
Provention Bio Completes $35M Equity Investment from Sanofi US
14 Feb 2023 //
CONTRACT PHARMA
Provention Announces Completion of $35 Million Equity Investment from Sanofi US
13 Feb 2023 //
PR NEWSWIRE
Provention Bio to Present at the SVB Securities Global Biopharma Conference
08 Feb 2023 //
PRESS RELEASE
Provention Bio Announces the Grant of Inducement Awards
03 Feb 2023 //
PR NEWSWIRE
Provention Bio Announces Closing of Second Tranche with Hercules Capital
02 Feb 2023 //
PR NEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
06 Jan 2023 //
PR NEWSWIRE
Almac Pharma Services Supports Launch of Provention Bio’s TZIELD
13 Dec 2022 //
CONTRACTPHARMA
Orsini Selected by Provention Bio as a Limited Distribution Partner for TZIELD
28 Nov 2022 //
PRNEWSWIRE
First-of-its-kind Type 1 diabetes drug wins FDA approval
19 Nov 2022 //
BIOPHARMADIVE
U.S. FDA greenlights Provention Bio`s diabetes drug
18 Nov 2022 //
REUTERS
Provention`s Biologic Tzield (Teplizumab) Receives Approval in the U.S.
17 Nov 2022 //
FDA
Provention Bio Announces the Grant of Inducement Awards
04 Nov 2022 //
PRESS RELEASE
Provention Bio to Report Q3 2022 Financial Results on November 3, 2022
13 Oct 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
07 Oct 2022 //
PRESS RELEASE
Provention partners with Sanofi on US marketing for type 1 diabetes drug
07 Oct 2022 //
ENPTS
Provention Bio lays commercial groundwork as FDA decision looms
06 Oct 2022 //
FIERCEPHARMA
Provention Bio Announces Senior Leadership Addition
19 Sep 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
02 Sep 2022 //
PRNEWSWIRE
Provention takes a $125M loan to advance Eli Lilly’s once-rejected diabetes drug
01 Sep 2022 //
ENDPTS
Provention Bio Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
PRNEWSWIRE
FDA delays review of Provention Bio’s embattled diabetes drug
01 Jul 2022 //
FIERCEBIOTECH
Provention Bio Extends FDA User Fee Goal Date for Teplizumab to November 17
30 Jun 2022 //
PRNEWSWIRE
Provention Bio Announces Update to Board of Directors
03 Jun 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
03 Jun 2022 //
PRNEWSWIRE
Provention Bio to Host a May 19, 2022 Virtual Investor Event for Teplizumab
12 May 2022 //
PRNEWSWIRE
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
28 Apr 2022 //
PRNEWSWIRE
Provention Bio Announces Positive Final Results from Study of PRV-101
28 Mar 2022 //
PRNEWSWIRE
FDA Accepts Provention`s BLA Resubmission for Teplizumab in Type 1 Diabetes
21 Mar 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
04 Mar 2022 //
PRESS RELEASE
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
03 Mar 2022 //
PRESS RELEASE
Provention Bio Announces BLA Resubmission for Teplizumab to Address CRL
22 Feb 2022 //
PRNEWSWIRE
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Conference
10 Feb 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Award
04 Feb 2022 //
PRNEWSWIRE
Provention med for delaying diabetes clear for FDA resubmission
28 Jan 2022 //
YAHOO FINANCE
Provention Bio Initiates Phase 2a Study of PRV-3279 in SLE
20 Jan 2022 //
PRNEWSWIRE
Provention Bio Announces the Grant of Inducement Awards
07 Jan 2022 //
PRNEWSWIRE
Provention Bio Announces Leadership Team Expansion
20 Dec 2021 //
PRNEWSWIRE
Bluebird bio may finally get a gene therapy approved in the US
22 Nov 2021 //
ENDPTS
Provention hires 3rd exec as it awaits FDA meeting for lead drug
18 Nov 2021 //
FIERCEBIOTECH
Provention Bio hires early research exec from Gossamer
09 Nov 2021 //
FIERCEBIOTECH
Provention Bio Appoints Miguel Sanjuan as Senior VP
05 Nov 2021 //
PRNEWSWIRE
Provention Bio Appoints of Thierry Chauche as Chief Financial Officer
04 Nov 2021 //
PRNEWSWIRE
Provention Bio Announces Positive Interim Results from PRV-101 Vaccine Study
26 Oct 2021 //
BIOSPACE
Provention Bio to Present at the Cantor Fitzgerald Virtual Healthcare Conference
23 Sep 2021 //
PRNEWSWIRE
Provention Bio Provides Update on Teplizumab At-Risk T1D BLA Resubmission
13 Sep 2021 //
PRNEWSWIRE
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
29 Jul 2021 //
PRNEWSWIRE
FDA knocks back diabetes prevention drug, crushing its maker`s shares
09 Jul 2021 //
BIOPHARMADIVE
Provention Bio Receives CR) to Biologics License Application for Teplizumab
07 Jul 2021 //
PR NEWSWIRE
Provention Bio Receives CR) to Biologics License Application for Teplizumab
07 Jul 2021 //
PR NEWSWIRE
Provention Bio slapped with FDA rejection for diabetes hopeful t
06 Jul 2021 //
FIERCEBIOTECH
FDA rejects Provention`s diabetes drug
06 Jul 2021 //
ENDPTS
FDA adcomm votes in favor of approving Provention Bio’s drug delay ty1 diabetes
28 May 2021 //
ENDPTS
FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing
27 May 2021 //
PRNEWSWIRE
Provention Bio Announces Posting of Briefing Documents for FDA Advisory
25 May 2021 //
PRNEWSWIRE
